[go: up one dir, main page]

PE20000537A1 - Composicion farmaceutica dispersable que contiene antagonistas de sustancia p de piperidina - Google Patents

Composicion farmaceutica dispersable que contiene antagonistas de sustancia p de piperidina

Info

Publication number
PE20000537A1
PE20000537A1 PE1999000436A PE00043699A PE20000537A1 PE 20000537 A1 PE20000537 A1 PE 20000537A1 PE 1999000436 A PE1999000436 A PE 1999000436A PE 00043699 A PE00043699 A PE 00043699A PE 20000537 A1 PE20000537 A1 PE 20000537A1
Authority
PE
Peru
Prior art keywords
weight
substance
antagonist
fatty acid
oil
Prior art date
Application number
PE1999000436A
Other languages
English (en)
Inventor
Steffen Lang
Kurt Liechti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811200.6A external-priority patent/GB9811200D0/en
Priority claimed from GBGB9818105.0A external-priority patent/GB9818105D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20000537A1 publication Critical patent/PE20000537A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE SE PUEDE DISPERSAR DE UNA MANERA ESPONTANEA Y COMPRENDE a)0,05% A 20% EN PESO DE UN ANTAGONISTA DE SUSTANCIA P DE PIPERIDINA TAL COMO (2R,4S)-N-(1-(3,5-BIS(TRIFLUOROMETIL)-BENZOIL)-2-(4-CLOROBENCIL)-4-PIPERIDINIL)-QUINOLIN-4-CARBOXAMIDA Y b)UN MEDIO PORTADOR QUE COMPRENDE i)DE 5% A 50% EN PESO DE UN COMPONENTE HIDROFILICO TAL COMO CITRATO DE TRIETILO, PROPILENGLICOL; ii)DE 5% A 80% EN PESO DE UN TENSOACTIVO TAL COMO UN PRODUCTO DE REACCION DE UN ACEITE DE RICINO NATURAL O HIDROGENADO CON OXIDO DE ETILENO O UN ESTER DE ACIDO GRASO DE POLIOXIETILENO; iii)DE 5% A 85% EN PESO DE UN COMPONENTE LIPOFILICO TAL COMO ACEITE VEGETAL ETOXILADO TRANSESTERIFICADO, MONO-, DI-, TRIGLICERIDO DE ACIDO GRASO C8-C10, ACEITE DE MAIZ TRANSESTERIFICADO CON GLICEROL REFINADO. LA COMPOSICION SE CARACTERIZA POR LA FORMACION DE ESTRUCTURAS COLOIDALES DE PARTICULAS SOLIDAS O LIQUIDAS EN FORMA DE GOTAS O NANOPARTICULAS O ESTRUCTURAS MICELARES DE HASTA 1000 NANOMETROS DE DIAMETRO AL PONERSE EN CONTACTO CON UN MEDIO ACUOSO PRESENTANDOSE COMO UN PRECONCENTRADO DE MICROEMULSION. EL ANTAGONISTA DE LA SUSTANCIA P PUEDE SER UTIL PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES RESPIRATORIAS
PE1999000436A 1998-05-26 1999-05-25 Composicion farmaceutica dispersable que contiene antagonistas de sustancia p de piperidina PE20000537A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811200.6A GB9811200D0 (en) 1998-05-26 1998-05-26 Organic compounds
GBGB9818105.0A GB9818105D0 (en) 1998-08-19 1998-08-19 Organic compounds

Publications (1)

Publication Number Publication Date
PE20000537A1 true PE20000537A1 (es) 2000-07-10

Family

ID=26313736

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000436A PE20000537A1 (es) 1998-05-26 1999-05-25 Composicion farmaceutica dispersable que contiene antagonistas de sustancia p de piperidina

Country Status (30)

Country Link
US (2) US20020156099A1 (es)
EP (1) EP1082119B1 (es)
JP (1) JP4083985B2 (es)
KR (1) KR20010043669A (es)
CN (1) CN1270714C (es)
AR (1) AR018376A1 (es)
AT (1) ATE257380T1 (es)
AU (1) AU755134B2 (es)
BE (1) BE1012143A5 (es)
BR (1) BR9910696A (es)
CA (1) CA2333154C (es)
DE (2) DE69914077T2 (es)
DK (1) DK1082119T3 (es)
ES (1) ES2214859T3 (es)
FR (1) FR2779145B1 (es)
GB (1) GB2353473A (es)
HU (1) HUP0102202A3 (es)
ID (1) ID27096A (es)
IL (1) IL139501A0 (es)
IT (1) IT1313551B1 (es)
NO (1) NO20005920L (es)
NZ (1) NZ508325A (es)
PE (1) PE20000537A1 (es)
PL (1) PL344245A1 (es)
PT (1) PT1082119E (es)
RU (1) RU2240121C2 (es)
SK (1) SK17752000A3 (es)
TR (1) TR200003502T2 (es)
TW (1) TW537894B (es)
WO (1) WO1999061025A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
AU2003225260A1 (en) * 2002-04-22 2003-11-03 University Of Florida Microemulsions for selective molecular separation
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
FR2934955B1 (fr) 2008-08-14 2011-07-08 Commissariat Energie Atomique Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
FR2935001B1 (fr) * 2008-08-14 2011-12-30 Commissariat Energie Atomique Emulsion fluorescente
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
BR112015015788A2 (pt) * 2012-12-31 2017-07-11 Jrx Biotechnology Inc formulações farmacêuticas de nano-emulsão tópicas líquidas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3305689A1 (de) 1983-02-18 1984-08-23 Mack Chem Pharm Pharmazeutische zubereitung mit retardwirkung
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
DE4220616C2 (de) 1992-06-24 1994-12-22 Byk Gulden Lomberg Chem Fab Dexniguldipin zur intravenösen Verabreichung
EP0589843B1 (en) 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
GB2278780B (en) * 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
ATE333867T1 (de) * 1994-03-18 2006-08-15 Shire Lab Inc Emulgierte arzneistoffabgabesysteme
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
CA2216701A1 (en) * 1995-03-27 1996-10-03 Akira Okayama Piperidine derivatives
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
AU2898297A (en) 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento

Also Published As

Publication number Publication date
NO20005920L (no) 2001-01-25
TW537894B (en) 2003-06-21
KR20010043669A (ko) 2001-05-25
DE69914077T2 (de) 2004-06-09
HK1035137A1 (en) 2001-11-16
US20030152626A1 (en) 2003-08-14
DK1082119T3 (da) 2004-04-13
US20020156099A1 (en) 2002-10-24
TR200003502T2 (tr) 2001-04-20
NO20005920D0 (no) 2000-11-23
HUP0102202A3 (en) 2003-01-28
WO1999061025A1 (en) 1999-12-02
ID27096A (id) 2001-03-01
NZ508325A (en) 2003-06-30
CN1270714C (zh) 2006-08-23
JP2002516280A (ja) 2002-06-04
AR018376A1 (es) 2001-11-14
AU4500899A (en) 1999-12-13
FR2779145A1 (fr) 1999-12-03
US6949257B2 (en) 2005-09-27
CA2333154A1 (en) 1999-12-02
GB0028506D0 (en) 2001-01-10
SK17752000A3 (sk) 2001-05-10
EP1082119A1 (en) 2001-03-14
ES2214859T3 (es) 2004-09-16
IL139501A0 (en) 2001-11-25
BR9910696A (pt) 2001-01-30
RU2240121C2 (ru) 2004-11-20
BE1012143A5 (fr) 2000-05-02
CN1303285A (zh) 2001-07-11
PL344245A1 (en) 2001-10-08
AU755134B2 (en) 2002-12-05
DE69914077D1 (de) 2004-02-12
PT1082119E (pt) 2004-05-31
FR2779145B1 (fr) 2004-07-30
ITMI991164A1 (it) 2000-11-26
EP1082119B1 (en) 2004-01-07
HUP0102202A2 (hu) 2001-11-28
DE19983247T1 (de) 2001-05-31
IT1313551B1 (it) 2002-09-09
CA2333154C (en) 2008-07-08
ATE257380T1 (de) 2004-01-15
JP4083985B2 (ja) 2008-04-30
GB2353473A (en) 2001-02-28

Similar Documents

Publication Publication Date Title
KR102407735B1 (ko) 나노에멀젼 전달 시스템의 조성물
DE4308282C2 (de) Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices
CN106691888B (zh) 一种高皮肤滞留光甘草定纳米组合物及其制备方法和用途
HU213669B (en) Preparation suitable for local treatment and comprising suspension of solid lipid particles, as well as process for producing same and pharmaceutical compositions for local treatment of body
US20060110418A1 (en) Water-in-oil emulsions and methods
TW201714605A (zh) 具有可逆的連續及分散相之奈米乳液
PE20000537A1 (es) Composicion farmaceutica dispersable que contiene antagonistas de sustancia p de piperidina
RU2013145709A (ru) Офтальмическая композиция
AU2014359195A1 (en) Lipid microcapsules preferably comprising a lipophilic active substance and composition containing same, method for the production thereof, and use of same in dermatology and in cosmetics
CN102906317A (zh) 纳米纤维
RU2010104979A (ru) Композиция эмульсии "масло в воде" и способ ее получения
NZ600999A (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
RU2015131700A (ru) Фармацевтические композиции, включающие производное камптотецина
TW200911301A (en) Pharmaceutical composition for topical application of poorly soluble compounds
JP2010531684A5 (es)
JP2008273881A (ja) 多層被覆油粒子、その水分散液、及びそれらの製造方法
JP2012523408A (ja) ジクロフェナクの安定な医薬組成物
Jaromin et al. Azacarbazole n-3 and n-6 polyunsaturated fatty acids ethyl esters nanoemulsion with enhanced efficacy against Plasmodium falciparum
Kichou et al. Efficiency of emulsifier‐free emulsions in delivering caffeine and α‐tocopherol to human skin
Khalil et al. Influence of formulation parameters on the physicochemical properties of meloxicam-loaded solid lipid nanoparticles
RU2007137182A (ru) Микроэмульсии соединений, связывающихся с каннабиноидными рецепторами
JP2008532967A5 (es)
KR100350179B1 (ko) Sedds로 제제화한 발기부전치료용 주입액제
US20190388543A1 (en) Formulations and methods for compositions used in wearable drug delivery devices
TW200824717A (en) Composition for external application to skin and skin regeneration promoter

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed